In a large study determining sarcoma risk, rare variant burden analysis identified germline ERCC2 variants in 23 patients with various sarcoma types, suggesting that ERCC2 may be a newly recognized sarcoma susceptibility gene [6]. Here, ERCC2 is linked to sarcoma.